Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Invivofectamine™ 3.0 Reagent

Click to view available options
No. of Reactions:
10
50 Reactions
Description
Using Invivofectamine™ 3.0 Reagent
Invitrogen™ Invivofectamine™ 3.0 Reagent is ideally suited for in vivo delivery of siRNA and miRNA duplexes. Invivofectamine™ 3.0/RNA complexes are delivered using a low-volume, low-pressure method with no toxicity and no stress response in the animal. Invivofectamine™ 3.0 can also be combined with BLOCK-iT™ fluorescent controls to track the biodistribution of the siRNA or miRNA.
For Research Use Only. Not for use in diagnostic procedures.
Invitrogen™ Invivofectamine™ 3.0 Reagent is ideally suited for in vivo delivery of siRNA and miRNA duplexes. Invivofectamine™ 3.0/RNA complexes are delivered using a low-volume, low-pressure method with no toxicity and no stress response in the animal. Invivofectamine™ 3.0 can also be combined with BLOCK-iT™ fluorescent controls to track the biodistribution of the siRNA or miRNA.
For Research Use Only. Not for use in diagnostic procedures.

Specifications
Specifications
Classification | Animal Origin-Free |
Cell Type | Hepatocytes |
Format | Kit |
Sample Type | Synthetic siRNA, siRNA, miRNA, RNAi |
Transfection Technique | Lipid-based Transfection, Lipid Nanoparticles, LNPs |
Species | Small Animal Models |
For Use With (Application) | Transfection |
No. of Reactions | 50 Reactions |
Product Line | Invivofectamine™ |
Product Type | Reagent |
Show More |
For Research Use Only. Not for use in diagnostic procedures.
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction